Merck
所有图片(5)

V2002

Sigma-Aldrich

万古霉素 盐酸盐 来源于东方链霉菌

≥900 μg per mg (as vancomycin base)

所有图片(5)
Empirical Formula (Hill Notation):
C66H75Cl2N9O24 · HCl
CAS号:
1404-93-9
分子量:
1485.71
Beilstein:
3704657
PubChem化学物质编号:
24900723
NACRES:
NA.85

质量水平

200

生物来源

Streptomyces orientalis

测定

≥900 μg/mg (

as vancomycin base

)

形式

powder

储存条件

(Keep container tightly closed in a dry and well-ventilated place.)

颜色

off-white to brown

抗生素抗菌谱

Gram-positive bacteria

作用机制

cell wall synthesis | interferes

储存温度

2-8°C

SMILES string

Cl[H].CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]2C[C@](C)(N)[C@@H](O)[C@@H](C)O2.CN[C@H](CC(C)C)C(=O)NC3[C@H](O)c4ccc(Oc5cc6Oc7ccc(cc7Cl)[C@@H](O)[C@H]8NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](CC(N)=O)NC3=O)c(c5)c6)c9ccc(O)c(c9)-c%10c(O)cc(O)cc%10[C@@H](NC8=O)C(O)=O)c(Cl)c4

正在寻找类似产品? Visit 产品对比指南

相关类别

一般描述

化学结构：糖肽

应用

来自东方链霉菌的万古霉素用于治疗由耐甲氧西林（β-内酰胺抗性）葡萄球菌的易感菌株而引起的严重或急性感染。 它用于在肽聚糖生物合成水平阻断细菌细胞壁生物合成。 它被广泛用于癌症患者。. 万古霉素的过度使用已被研究，从而得到了推荐的指南。

包装

1, 5 g in glass bottle
100, 250 mg in glass bottle
无底玻璃瓶。内含物装在插入的融合锥内。

生化/生理作用

万古霉素是一种可在肽聚糖生物合成水平阻断细菌细胞壁生物合成的糖肽抗生素。 它会抑制NAM/NAG-肽的末端D-丙氨酰-D-丙氨酸部分插入。 它可有效用于革兰氏阳性菌。 万古霉素可改变细菌细胞膜的通透性和RNA合成。
糖肽抗生素
作用模式：用于通过抑制NAM/NAG-肽的末端D-丙氨酰-D-丙氨酸部分的插入在肽聚糖生物合成水平阻断细菌细胞壁生物合成。
抗菌谱：革兰氏阳性菌

其他说明

保持容器密闭并置于干燥通风处。

象形图

Health hazard
GHS08

警示用语：

Danger

危险声明

H317 - H334

危险分类

Resp. Sens. 1 - Skin Sens. 1

储存分类代码

11 - Combustible Solids

WGK

WGK 2

闪点(F)

Not applicable

闪点(C)

Not applicable

个人防护装备

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

分析证书

请输入批号搜索分析证书（COA）。

原产地证书 (CofO)

请输入批号搜索原产地证书（COO）。

更多文件

Structure Search

Quotes and Ordering

Bulk Quote-Order Product

  1. Which document(s) contains shelf-life or expiration date information for a given product?

    If available for a given product, the recommended re-test date or the expiration date can be found on the Certificate of Analysis.

  2. How do I get lot-specific information or a Certificate of Analysis?

    The lot specific COA document can be found by entering the lot number above under the "Documents" section.

  3. What is Product V2002, Vancomycin, soluble in?

    This product is soluble in water (50 mg/ml), forming a clear, colorless to faint yellow solution. It is also moderately soluble in methanol, but insoluble in the higher alcohols, acetone, and ether. Low concentrations of urea increase the solubility in neutral aqueous solutions, and ammonium sulfate and sodium chloride precipitate the antibiotic from acidic solutions.

  4. How long are Product V2002, Vancomycin, solutions stable for?

    Solutions of vancomycin in physiological solutions such as 0.9% saline and 5% glucose are stable for 17 days at 24 °C and 63 days and 5 °C and -10 °C.

  5. What is the retest period for Product V2002, Vancomycin?

    At this time, Product No. V2002 is assigned a retest period of 2 years from the quality control release date. This interval may change if we are able to collect sufficient data from future retesting.

  6. How do I find price and availability?

    There are several ways to find pricing and availability for our products. Once you log onto our website, you will find the price and availability displayed on the product detail page. You can contact any of our Customer Sales and Service offices to receive a quote.  USA customers:  1-800-325-3010 or view local office numbers.

  7. What is the Department of Transportation shipping information for this product?

    Transportation information can be found in Section 14 of the product's (M)SDS.To access the shipping information for this material, use the link on the product detail page for the product. 

  8. My question is not addressed here, how can I contact Technical Service for assistance?

    Ask a Scientist here.

Hadeel Al-Kofide et al.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 16(4), 245-250 (2009-12-18)
gram-positive infections are prevalent among cancer patients and vancomycin therapy is often initiated empirically. A typical vancomycin pharmacokinetics is observed in such patients. The aim of the study was to evaluate the pharmacokinetics of vancomycin in this patient population and
Shasha Rao et al.
The Journal of antibiotics, 69(12), 879-884 (2016-05-18)
Antibiotic-resistant bacteria is a major threat to human health and is predicted to become the leading cause of death from disease by 2050. Despite the recent resurgence of research and development in the area, few antibiotics have reached the market
Ashraf Zarkan et al.
Scientific reports, 7(1), 4893-4893 (2017-07-09)
Vancomycin is known to bind to Zn(II) and can induce a zinc starvation response in bacteria. Here we identify a novel polymerization of vancomycin dimers by structural analysis of vancomycin-Zn(II) crystals and fibre X-ray diffraction. Bioassays indicate that this structure
Torsten S Boutrup et al.
Acta veterinaria Scandinavica, 52, 17-17 (2010-02-26)
Porcine proliferative enteropathy in pigs is caused by the obligate, intracellular bacterium Lawsonia intracellularis. In vitro studies have shown close bacterium-cell interaction followed by cellular uptake of the bacterium within 3 h post inoculation (PI). However, knowledge of the initial
Aβeβment of vancomycin use in chronic haemodialysis patients: room for improvement
Keyserling HL, et al.
Nephrology, Dialysis, and Transplantation, 112, e104-e111 (2003)
查看所有相关文献

相关内容

Inhibition of Cell Wall Biosynthesis by Antibiotics

Inhibition of Cell Wall Biosynthesis by Antibiotics

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门